ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

Skyhawk expands drug discovery with Merck

by Ryan Cross
May 15, 2020 | APPEARED IN VOLUME 98, ISSUE 19

Merck & Co. has expanded its collaboration with Skyhawk Therapeutics to develop small-molecule drugs that modify RNA splicing in autoimmune and metabolic diseases. The deal builds on an agreement the firms announced last summer to develop drugs for neurodegenerative diseases and cancer. Skyhawk will get an undisclosed up-front payment and could receive up to $600 million per drug program. Skyhawk, which was one of C&EN’s 10 Start-Ups to Watch in 2019, also has collaborations with Biogen, Celgene, and Takeda Pharmaceutical.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment